163 related articles for article (PubMed ID: 21652682)
1. Decay-accelerating factor regulates T-cell immunity in the context of inflammation by influencing costimulatory molecule expression on antigen-presenting cells.
Fang C; Miwa T; Song WC
Blood; 2011 Jul; 118(4):1008-14. PubMed ID: 21652682
[TBL] [Abstract][Full Text] [Related]
2. Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.
Lalli PN; Strainic MG; Yang M; Lin F; Medof ME; Heeger PS
Blood; 2008 Sep; 112(5):1759-66. PubMed ID: 18567839
[TBL] [Abstract][Full Text] [Related]
3. Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.
Lalli PN; Strainic MG; Lin F; Medof ME; Heeger PS
J Immunol; 2007 Nov; 179(9):5793-802. PubMed ID: 17947652
[TBL] [Abstract][Full Text] [Related]
4. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
[TBL] [Abstract][Full Text] [Related]
5. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection.
Pavlov V; Raedler H; Yuan S; Leisman S; Kwan WH; Lalli PN; Medof ME; Heeger PS
J Immunol; 2008 Oct; 181(7):4580-9. PubMed ID: 18802060
[TBL] [Abstract][Full Text] [Related]
6. IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production.
Liu J; Lin F; Strainic MG; An F; Miller RH; Altuntas CZ; Heeger PS; Tuohy VK; Medof ME
J Immunol; 2008 May; 180(9):5882-9. PubMed ID: 18424707
[TBL] [Abstract][Full Text] [Related]
7. Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice.
Fang C; Miwa T; Shen H; Song WC
J Immunol; 2007 Sep; 179(5):3178-86. PubMed ID: 17709533
[TBL] [Abstract][Full Text] [Related]
8. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis.
Sogabe H; Nangaku M; Ishibashi Y; Wada T; Fujita T; Sun X; Miwa T; Madaio MP; Song WC
J Immunol; 2001 Sep; 167(5):2791-7. PubMed ID: 11509624
[TBL] [Abstract][Full Text] [Related]
9. Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.
Ahmad SR; Lidington EA; Ohta R; Okada N; Robson MG; Davies KA; Leitges M; Harris CL; Haskard DO; Mason JC
Immunology; 2003 Oct; 110(2):258-68. PubMed ID: 14511240
[TBL] [Abstract][Full Text] [Related]
10. Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells.
Bao L; Haas M; Pippin J; Wang Y; Miwa T; Chang A; Minto AW; Petkova M; Qiao G; Song WC; Alpers CE; Zhang J; Shankland SJ; Quigg RJ
J Clin Invest; 2009 May; 119(5):1264-74. PubMed ID: 19349693
[TBL] [Abstract][Full Text] [Related]
11. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.
Miwa T; Sun X; Ohta R; Okada N; Harris CL; Morgan BP; Song WC
Immunology; 2001 Oct; 104(2):207-14. PubMed ID: 11683961
[TBL] [Abstract][Full Text] [Related]
12. Increased morbidity and mortality in murine cytomegalovirus-infected mice following allogeneic bone marrow transplant is associated with reduced surface decay accelerating factor expression.
El-Amouri IS; Bani-Ahmad M; Tang-Feldman Y; Lin F; Ko C; Pomeroy C; Oakley OR
Clin Exp Immunol; 2010 Nov; 162(2):379-91. PubMed ID: 20840652
[TBL] [Abstract][Full Text] [Related]
13. Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.
Seregin SS; Aldhamen YA; Appledorn DM; Hartman ZC; Schuldt NJ; Scott J; Godbehere S; Jiang H; Frank MM; Amalfitano A
Blood; 2010 Sep; 116(10):1669-77. PubMed ID: 20511542
[TBL] [Abstract][Full Text] [Related]
14. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
15. Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice.
Leung VW; Yun S; Botto M; Mason JC; Malik TH; Song W; Paixao-Cavalcante D; Pickering MC; Boyle JJ; Haskard DO
Am J Pathol; 2009 Oct; 175(4):1757-67. PubMed ID: 19729477
[TBL] [Abstract][Full Text] [Related]
16. Generation of a novel decay accelerating factor (DAF) knock-out rat model using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9), genome editing.
Detsika MG; Goudevenou K; Geurts AM; Gakiopoulou H; Grapsa E; Lianos EA
Transgenic Res; 2021 Feb; 30(1):11-21. PubMed ID: 33387103
[TBL] [Abstract][Full Text] [Related]
17. The role of decay accelerating factor in the immunopathogenesis of cytomegalovirus infection.
Bani-Ahmad M; El-Amouri IS; Ko CM; Lin F; Tang-Feldman Y; Oakley OR
Clin Exp Immunol; 2011 Feb; 163(2):199-206. PubMed ID: 21166665
[TBL] [Abstract][Full Text] [Related]
18. Decay-accelerating factor modulates induction of T cell immunity.
Heeger PS; Lalli PN; Lin F; Valujskikh A; Liu J; Muqim N; Xu Y; Medof ME
J Exp Med; 2005 May; 201(10):1523-30. PubMed ID: 15883171
[TBL] [Abstract][Full Text] [Related]
19. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice.
Pritchard MT; McMullen MR; Stavitsky AB; Cohen JI; Lin F; Edward Medof M; Nagy LE
Gastroenterology; 2007 Mar; 132(3):1117-1126. PubMed ID: 17383432
[TBL] [Abstract][Full Text] [Related]
20. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
Harris CL; Spiller OB; Morgan BP
Immunology; 2000 Aug; 100(4):462-70. PubMed ID: 10929073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
